{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:26:06Z","timestamp":1770423966841,"version":"3.49.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-024-03393-2","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T04:55:10Z","timestamp":1737348910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Secretogranin III: a promising therapeutic target for intraocular neovascular lesions"],"prefix":"10.1007","volume":"45","author":[{"given":"Chao-Yi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao-Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"3393_CR1","doi-asserted-by":"publisher","first-page":"E2655","DOI":"10.1073\/pnas.1522014113","volume":"113","author":"EH Sohn","year":"2016","unstructured":"Sohn EH, van Dijk HW, Jiao C et al (2016) Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc Natl Acad Sci USA 113:E2655-2664. https:\/\/doi.org\/10.1073\/pnas.1522014113","journal-title":"Proc Natl Acad Sci USA"},{"key":"3393_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00417-016-3548-y","volume":"255","author":"TW Gardner","year":"2017","unstructured":"Gardner TW, Davila JR (2017) The neurovascular unit and the pathophysiologic basis of diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 255:1\u20136. https:\/\/doi.org\/10.1007\/s00417-016-3548-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3393_CR3","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jama.298.8.902","volume":"298","author":"Q Mohamed","year":"2007","unstructured":"Mohamed Q, Gillies MC, Wong TY (2007) Management of diabetic retinopathy: a systematic review. JAMA 298:902\u2013916. https:\/\/doi.org\/10.1001\/jama.298.8.902","journal-title":"JAMA"},{"key":"3393_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s13167-010-0003-8","volume":"1","author":"T Josifova","year":"2010","unstructured":"Josifova T, Plestina-Borjan I, Henrich PB (2010) Proliferative diabetic retinopathy: predictive and preventive measures at hypoxia induced retinal changes. EPMA J 1:73\u201377. https:\/\/doi.org\/10.1007\/s13167-010-0003-8","journal-title":"EPMA J"},{"key":"3393_CR5","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.2337\/diacare.27.5.1036","volume":"27","author":"DE Laaksonen","year":"2004","unstructured":"Laaksonen DE, Niskanen L, Punnonen K et al (2004) Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036\u20131041. https:\/\/doi.org\/10.2337\/diacare.27.5.1036","journal-title":"Diabetes Care"},{"key":"3393_CR6","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m A, Smith LEH, Dammann O (2013) Retinopathy of prematurity. Lancet 382:1445\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(13)60178-6","journal-title":"Lancet"},{"key":"3393_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","volume":"122","author":"ME Hartnett","year":"2015","unstructured":"Hartnett ME (2015) Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology 122:200\u2013210. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.050","journal-title":"Ophthalmology"},{"key":"3393_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ydbio.2011.12.027","volume":"363","author":"A Nakamura-Ishizu","year":"2012","unstructured":"Nakamura-Ishizu A, Kurihara T, Okuno Y et al (2012) The formation of an angiogenic astrocyte template is regulated by the neuroretina in a HIF-1-dependent manner. Dev Biol 363:106\u2013114. https:\/\/doi.org\/10.1016\/j.ydbio.2011.12.027","journal-title":"Dev Biol"},{"key":"3393_CR9","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/glia.23189","volume":"65","author":"ML O\u2019Sullivan","year":"2017","unstructured":"O\u2019Sullivan ML, Pu\u00f1al VM, Kerstein PC et al (2017) Astrocytes follow ganglion cell axons to establish an angiogenic template during retinal development. Glia 65:1697\u20131716. https:\/\/doi.org\/10.1002\/glia.23189","journal-title":"Glia"},{"key":"3393_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","volume":"75","author":"J Ambati","year":"2012","unstructured":"Ambati J, Fowler BJ (2012) Mechanisms of age-related macular degeneration. Neuron 75:26\u201339. https:\/\/doi.org\/10.1016\/j.neuron.2012.06.018","journal-title":"Neuron"},{"key":"3393_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.709501","volume":"12","author":"B Zhang","year":"2021","unstructured":"Zhang B, Zhou Z, Zhang B, Wang D (2021) Efficacy and safety of various treatments for proliferative diabetic retinopathy: a systematic review and network meta-analysis. Front Pharmacol 12:709501. https:\/\/doi.org\/10.3389\/fphar.2021.709501","journal-title":"Front Pharmacol"},{"key":"3393_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1600-0420.2007.01067.x","volume":"86","author":"C Shima","year":"2008","unstructured":"Shima C, Sakaguchi H, Gomi F et al (2008) Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86:372\u2013376. https:\/\/doi.org\/10.1111\/j.1600-0420.2007.01067.x","journal-title":"Acta Ophthalmol"},{"key":"3393_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","volume":"246","author":"L Wu","year":"2008","unstructured":"Wu L, Mart\u00ednez-Castellanos MA, Quiroz-Mercado H et al (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American collaborative retina study group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81\u201387. https:\/\/doi.org\/10.1007\/s00417-007-0660-z","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3393_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1507\/endocrj.k10e-038","volume":"57","author":"M Hosaka","year":"2010","unstructured":"Hosaka M, Watanabe T (2010) Secretogranin III: a bridge between core hormone aggregates and the secretory granule membrane. Endocr J 57:275\u2013286. https:\/\/doi.org\/10.1507\/endocrj.k10e-038","journal-title":"Endocr J"},{"key":"3393_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00018-017-2635-5","volume":"75","author":"W Li","year":"2018","unstructured":"Li W, Webster KA, LeBlanc ME, Tian H (2018) Secretogranin III: a diabetic retinopathy-selective angiogenic factor. Cell Mol Life Sci 75:635\u2013647. https:\/\/doi.org\/10.1007\/s00018-017-2635-5","journal-title":"Cell Mol Life Sci"},{"key":"3393_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/j.1460-2075.1990.tb08123.x","volume":"9","author":"DM Kingsley","year":"1990","unstructured":"Kingsley DM, Rinchik EM, Russell LB et al (1990) Genetic ablation of a mouse gene expressed specifically in brain. EMBO J 9:395\u2013399. https:\/\/doi.org\/10.1002\/j.1460-2075.1990.tb08123.x","journal-title":"EMBO J"},{"key":"3393_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1084\/jem.20161802","volume":"214","author":"ME LeBlanc","year":"2017","unstructured":"LeBlanc ME, Wang W, Chen X et al (2017) Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. J Exp Med 214:1029\u20131047. https:\/\/doi.org\/10.1084\/jem.20161802","journal-title":"J Exp Med"},{"key":"3393_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00018-021-04111-2","volume":"79","author":"C Dai","year":"2022","unstructured":"Dai C, Waduge P, Ji L et al (2022) Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy. Cell Mol Life Sci 79:63. https:\/\/doi.org\/10.1007\/s00018-021-04111-2","journal-title":"Cell Mol Life Sci"},{"key":"3393_CR19","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101085RR","volume":"36","author":"L Ji","year":"2022","unstructured":"Ji L, Waduge P, Hao L et al (2022) Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization. FASEB J 36:e22106. https:\/\/doi.org\/10.1096\/fj.202101085RR","journal-title":"FASEB J"},{"key":"3393_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1210\/er.2010-0027","volume":"32","author":"A Bartolomucci","year":"2011","unstructured":"Bartolomucci A, Possenti R, Mahata SK et al (2011) The extended granin family: structure, function, and biomedical implications. Endocr Rev 32:755\u2013797. https:\/\/doi.org\/10.1210\/er.2010-0027","journal-title":"Endocr Rev"},{"key":"3393_CR21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1017\/s146479310400644x","volume":"79","author":"KB Helle","year":"2004","unstructured":"Helle KB (2004) The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 79:769\u2013794. https:\/\/doi.org\/10.1017\/s146479310400644x","journal-title":"Biol Rev Camb Philos Soc"},{"key":"3393_CR22","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1091\/mbc.02-03-0040","volume":"13","author":"M Hosaka","year":"2002","unstructured":"Hosaka M, Watanabe T, Sakai Y et al (2002) Identification of a chromogranin A domain that mediates binding to secretogranin III and targeting to secretory granules in pituitary cells and pancreatic beta-cells. Mol Biol Cell 13:3388\u20133399. https:\/\/doi.org\/10.1091\/mbc.02-03-0040","journal-title":"Mol Biol Cell"},{"key":"3393_CR23","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1074\/jbc.M310104200","volume":"279","author":"M Hosaka","year":"2004","unstructured":"Hosaka M, Suda M, Sakai Y et al (2004) Secretogranin III binds to cholesterol in the secretory granule membrane as an adapter for chromogranin A. J Biol Chem 279:3627\u20133634. https:\/\/doi.org\/10.1074\/jbc.M310104200","journal-title":"J Biol Chem"},{"key":"3393_CR24","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1242\/jcs.02608","volume":"118","author":"M Hosaka","year":"2005","unstructured":"Hosaka M, Watanabe T, Sakai Y et al (2005) Interaction between secretogranin III and carboxypeptidase E facilitates prohormone sorting within secretory granules. J Cell Sci 118:4785\u20134795. https:\/\/doi.org\/10.1242\/jcs.02608","journal-title":"J Cell Sci"},{"key":"3393_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1078-0432.CCR-08-1163","volume":"15","author":"AC Moss","year":"2009","unstructured":"Moss AC, Jacobson GM, Walker LE et al (2009) SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer. Clin Cancer Res 15:274\u2013283. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1163","journal-title":"Clin Cancer Res"},{"key":"3393_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.canlet.2014.05.007","volume":"352","author":"Y Wang","year":"2014","unstructured":"Wang Y, Cui M, Cai X et al (2014) The oncoprotein HBXIP up-regulates SCG3 through modulating E2F1 and miR-509-3p in hepatoma cells. Cancer Lett 352:169\u2013178. https:\/\/doi.org\/10.1016\/j.canlet.2014.05.007","journal-title":"Cancer Lett"},{"key":"3393_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10049","author":"J Jongsma","year":"2002","unstructured":"Jongsma J, Oomen MH, Noordzij MA et al (2002) Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate. https:\/\/doi.org\/10.1002\/pros.10049","journal-title":"Prostate"},{"key":"3393_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.regpep.2010.06.002","volume":"165","author":"GM Portela-Gomes","year":"2010","unstructured":"Portela-Gomes GM, Grimelius L, Stridsberg M (2010) Secretogranin III in human neuroendocrine tumours: a comparative immunohistochemical study with chromogranins A and B and secretogranin II. Regul Pept 165:30\u201335. https:\/\/doi.org\/10.1016\/j.regpep.2010.06.002","journal-title":"Regul Pept"},{"key":"3393_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127904","volume":"10","author":"ME LeBlanc","year":"2015","unstructured":"LeBlanc ME, Wang W, Caberoy NB et al (2015) Hepatoma-derived growth factor-related protein-3 is a novel angiogenic factor. PLoS ONE 10:e0127904. https:\/\/doi.org\/10.1371\/journal.pone.0127904","journal-title":"PLoS ONE"},{"key":"3393_CR30","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1091\/mbc.E14-09-1343","volume":"26","author":"F Guo","year":"2015","unstructured":"Guo F, Ding Y, Caberoy N et al (2015) ABCF1 extrinsically regulates retinal pigment epithelial cell phagocytosis. Mol Biol Cell 26:2311\u20132320. https:\/\/doi.org\/10.1091\/mbc.E14-09-1343","journal-title":"Mol Biol Cell"},{"key":"3393_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126993","volume":"10","author":"Y Ding","year":"2015","unstructured":"Ding Y, Caberoy NB, Guo F et al (2015) Reticulocalbin-1 facilitates microglial phagocytosis. PLoS ONE 10:e0126993. https:\/\/doi.org\/10.1371\/journal.pone.0126993","journal-title":"PLoS ONE"},{"key":"3393_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.bbrc.2017.11.080","volume":"495","author":"F Tang","year":"2018","unstructured":"Tang F, Pacheco MTF, Chen P et al (2018) Secretogranin III promotes angiogenesis through MEK\/ERK signaling pathway. Biochem Biophys Res Commun 495:781\u2013786. https:\/\/doi.org\/10.1016\/j.bbrc.2017.11.080","journal-title":"Biochem Biophys Res Commun"},{"key":"3393_CR33","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.biocel.2008.04.009","volume":"40","author":"JW Ramos","year":"2008","unstructured":"Ramos JW (2008) The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 40:2707\u20132719. https:\/\/doi.org\/10.1016\/j.biocel.2008.04.009","journal-title":"Int J Biochem Cell Biol"},{"key":"3393_CR34","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood-2010-02-271478","volume":"116","author":"Q Zhang","year":"2010","unstructured":"Zhang Q, Wang D, Kundumani-Sridharan V et al (2010) PLD1-dependent PKCgamma activation downstream to Src is essential for the development of pathologic retinal neovascularization. Blood 116:1377\u20131385. https:\/\/doi.org\/10.1182\/blood-2010-02-271478","journal-title":"Blood"},{"key":"3393_CR35","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMra021405","volume":"348","author":"L Taupenot","year":"2003","unstructured":"Taupenot L, Harper KL, O\u2019Connor DT (2003) The chromogranin-secretogranin family. N Engl J Med 348:1134\u20131149. https:\/\/doi.org\/10.1056\/NEJMra021405","journal-title":"N Engl J Med"},{"key":"3393_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10456-019-09662-4","volume":"22","author":"F Tang","year":"2019","unstructured":"Tang F, LeBlanc ME, Wang W et al (2019) Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety. Angiogenesis 22:369\u2013382. https:\/\/doi.org\/10.1007\/s10456-019-09662-4","journal-title":"Angiogenesis"},{"key":"3393_CR37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/ijms23010350","volume":"23","author":"Y He","year":"2021","unstructured":"He Y, Tian H, Dai C et al (2021) Optimal efficacy and safety of humanized anti-Scg3 antibody to alleviate oxygen-induced retinopathy. Int J Mol Sci 23:350. https:\/\/doi.org\/10.3390\/ijms23010350","journal-title":"Int J Mol Sci"},{"key":"3393_CR38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.31083\/j.fbl2704130","volume":"27","author":"C Dai","year":"2022","unstructured":"Dai C, Tian H, Bhatt A et al (2022) Safety and efficacy of systemic anti-Scg3 therapy to treat oxygen-induced retinopathy. Front Biosci (Landmark Ed) 27:130. https:\/\/doi.org\/10.31083\/j.fbl2704130","journal-title":"Front Biosci (Landmark Ed)"},{"key":"3393_CR39","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1111\/aos.13400","volume":"95","author":"S Lin","year":"2017","unstructured":"Lin S, Gupta B, James N, Ling RH (2017) Visual impairment certification due to diabetic retinopathy in North and Eastern Devon. Acta Ophthalmol 95:e756\u2013e762. https:\/\/doi.org\/10.1111\/aos.13400","journal-title":"Acta Ophthalmol"},{"key":"3393_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cmet.2012.11.012","volume":"17","author":"C Rask-Madsen","year":"2013","unstructured":"Rask-Madsen C, King GL (2013) Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab 17:20\u201333. https:\/\/doi.org\/10.1016\/j.cmet.2012.11.012","journal-title":"Cell Metab"},{"key":"3393_CR41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124\u2013136. https:\/\/doi.org\/10.1016\/S0140-6736(09)62124-3","journal-title":"Lancet"},{"key":"3393_CR42","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1007\/s00125-018-4692-1","volume":"61","author":"R Sim\u00f3","year":"2018","unstructured":"Sim\u00f3 R, Stitt AW, Gardner TW (2018) Neurodegeneration in diabetic retinopathy: Does it really matter? Diabetologia 61:1902\u20131912. https:\/\/doi.org\/10.1007\/s00125-018-4692-1","journal-title":"Diabetologia"},{"key":"3393_CR43","doi-asserted-by":"publisher","first-page":"10531","DOI":"10.3390\/ijms241310531","volume":"24","author":"L Ji","year":"2023","unstructured":"Ji L, Waduge P, Wu Y et al (2023) Secretogranin III selectively promotes vascular leakage in the deep vascular plexus of diabetic retinopathy. Int J Mol Sci 24:10531. https:\/\/doi.org\/10.3390\/ijms241310531","journal-title":"Int J Mol Sci"},{"key":"3393_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.exer.2019.03.009","volume":"182","author":"X Rong","year":"2019","unstructured":"Rong X, Tian H, Yang L, Li W (2019) Function-first ligandomics for ocular vascular research and drug target discovery. Exp Eye Res 182:57\u201364. https:\/\/doi.org\/10.1016\/j.exer.2019.03.009","journal-title":"Exp Eye Res"},{"key":"3393_CR45","first-page":"257","volume":"26","author":"OJ Mezu-Ndubuisi","year":"2020","unstructured":"Mezu-Ndubuisi OJ, Macke EL, Kalavacherla R et al (2020) Long-term evaluation of retinal morphology and function in a mouse model of oxygen-induced retinopathy. Mol Vis 26:257\u2013276","journal-title":"Mol Vis"},{"key":"3393_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/glia.20900","volume":"58","author":"MI Dorrell","year":"2010","unstructured":"Dorrell MI, Aguilar E, Jacobson R et al (2010) Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy. Glia 58:43\u201354. https:\/\/doi.org\/10.1002\/glia.20900","journal-title":"Glia"},{"key":"3393_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10633-009-9193-6","volume":"120","author":"EL Fletcher","year":"2010","unstructured":"Fletcher EL, Downie LE, Hatzopoulos K et al (2010) The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy. Doc Ophthalmol 120:67\u201386. https:\/\/doi.org\/10.1007\/s10633-009-9193-6","journal-title":"Doc Ophthalmol"},{"key":"3393_CR48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.exer.2017.12.007","volume":"168","author":"A Nakano","year":"2018","unstructured":"Nakano A, Asano D, Kondo R et al (2018) Retinal neuronal cell loss prevents abnormal retinal vascular growth in a rat model of retinopathy of prematurity. Exp Eye Res 168:115\u2013127. https:\/\/doi.org\/10.1016\/j.exer.2017.12.007","journal-title":"Exp Eye Res"},{"key":"3393_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","volume":"9","author":"Y Deng","year":"2022","unstructured":"Deng Y, Qiao L, Du M et al (2022) Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis 9:62\u201379. https:\/\/doi.org\/10.1016\/j.gendis.2021.02.009","journal-title":"Genes Dis"},{"key":"3393_CR50","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127:616\u2013636. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004","journal-title":"Ophthalmology"},{"key":"3393_CR51","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.exer.2019.01.009","volume":"181","author":"ME LeBlanc","year":"2019","unstructured":"LeBlanc ME, Wang W, Ji Y et al (2019) Secretogranin III as a novel target for the therapy of choroidal neovascularization. Exp Eye Res 181:120\u2013126. https:\/\/doi.org\/10.1016\/j.exer.2019.01.009","journal-title":"Exp Eye Res"},{"key":"3393_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16356","author":"L Ji","year":"2022","unstructured":"Ji L, Waduge P, Wan W et al (2022) Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization. The FEBS J. https:\/\/doi.org\/10.1111\/febs.16356","journal-title":"The FEBS J"},{"key":"3393_CR53","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1172\/JCI65509","volume":"122","author":"SE Quaggin","year":"2012","unstructured":"Quaggin SE (2012) Turning a blind eye to anti-VEGF toxicities. J Clin Invest 122:3849\u20133851. https:\/\/doi.org\/10.1172\/JCI65509","journal-title":"J Clin Invest"},{"key":"3393_CR54","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1167\/iovs.12-10959","volume":"54","author":"Z Han","year":"2013","unstructured":"Han Z, Guo J, Conley SM, Naash MI (2013) Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy. Invest Ophthalmol Vis Sci 54:574\u2013584. https:\/\/doi.org\/10.1167\/iovs.12-10959","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3393_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/EB.S94447","volume":"8","author":"CB Kim","year":"2016","unstructured":"Kim CB, D\u2019Amore PA, Connor KM (2016) Revisiting the mouse model of oxygen-induced retinopathy. Eye Brain 8:67\u201379. https:\/\/doi.org\/10.2147\/EB.S94447","journal-title":"Eye Brain"},{"key":"3393_CR56","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00109-022-02195-2","volume":"100","author":"C Dai","year":"2022","unstructured":"Dai C, Xiao J, Wang C et al (2022) Neurovascular abnormalities in retinopathy of prematurity and emerging therapies. J Mol Med (Berl) 100:817\u2013828. https:\/\/doi.org\/10.1007\/s00109-022-02195-2","journal-title":"J Mol Med (Berl)"},{"key":"3393_CR57","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.3390\/biomedicines11071910","volume":"11","author":"C Huang","year":"2023","unstructured":"Huang C, Ji L, Kaur A et al (2023) Anti-Scg3 gene therapy to treat choroidal neovascularization in mice. Biomedicines 11:1910. https:\/\/doi.org\/10.3390\/biomedicines11071910","journal-title":"Biomedicines"},{"key":"3393_CR58","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00441-013-1779-3","volume":"355","author":"JR Privratsky","year":"2014","unstructured":"Privratsky JR, Newman PJ (2014) PECAM-1: regulator of endothelial junctional integrity. Cell Tissue Res 355:607\u2013619. https:\/\/doi.org\/10.1007\/s00441-013-1779-3","journal-title":"Cell Tissue Res"},{"key":"3393_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.107695","volume":"186","author":"T Livnat","year":"2019","unstructured":"Livnat T, Weinberger Y, Budnik I et al (2019) Activated protein C induces suppression and regression of choroidal neovascularization\u2014a murine model. Exp Eye Res 186:107695. https:\/\/doi.org\/10.1016\/j.exer.2019.107695","journal-title":"Exp Eye Res"},{"key":"3393_CR60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.exer.2018.02.018","volume":"170","author":"L Lassance","year":"2018","unstructured":"Lassance L, Marino GK, Medeiros CS et al (2018) Fibrocyte migration, differentiation and apoptosis during the corneal wound healing response to injury. Exp Eye Res 170:177\u2013187. https:\/\/doi.org\/10.1016\/j.exer.2018.02.018","journal-title":"Exp Eye Res"},{"key":"3393_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108568","volume":"207","author":"Y Liu","year":"2021","unstructured":"Liu Y, Shu Y, Yin L et al (2021) Protective roles of the TIR\/BB-loop mimetic AS-1 in alkali-induced corneal neovascularization by inhibiting ERK phosphorylation. Exp Eye Res 207:108568. https:\/\/doi.org\/10.1016\/j.exer.2021.108568","journal-title":"Exp Eye Res"},{"key":"3393_CR62","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12886-022-02690-7","volume":"22","author":"H Jin","year":"2022","unstructured":"Jin H, Yang B, Jiang D et al (2022) Inhibitory effect of anti-Scg3 on corneal neovascularization: a preliminary study. BMC Ophthalmol 22:455. https:\/\/doi.org\/10.1186\/s12886-022-02690-7","journal-title":"BMC Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-03393-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:04:31Z","timestamp":1766167471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-03393-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3393"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-03393-2","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"19 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"26"}}